Stockscreener 앱 받기
6.55
2.83%
0.18
전일 마감가:
$6.37
열려 있는:
$6.37
하루 거래량:
2.02M
Relative Volume:
1.64
시가총액:
$687.03M
수익:
-
순이익/손실:
$-58.88M
주가수익비율:
-5.8882
EPS:
-1.1124
순현금흐름:
$-42.79M
1주 성능:
+4.47%
1개월 성능:
-5.07%
6개월 성능:
+45.56%
1년 성능:
+825.01%
1일 변동 폭
$6.27
$6.585
1주일 범위
$6.22
$6.97
52주 변동 폭
$0.52
$8.00
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.45 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.19 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.19 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.83 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.19 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 개시 | Piper Sandler | Overweight |
| 2026-01-23 | 재개 | Leerink Partners | Outperform |
| 2025-12-22 | 개시 | Jefferies | Buy |
| 2025-11-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Relmada Therapeutics bolsters Sepranolone Program with Michael Quirk as Senior Advisor - Indian Pharma Post
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program - Investing News Network
Relmada appoints Michael Quirk as senior advisor for sepranolone - Investing.com
Relmada appoints Michael Quirk as senior advisor for sepranolone By Investing.com - Investing.com UK
Relmada Therapeutics Appoints CNS Drug Development Veteran - GlobeNewswire
Venrock-affiliated funds hold 6.2% of Relmada (NASDAQ: RLMD) - Stock Titan
RLMD Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesSurprise Factor Analysis - newsline.com
RLMD: NDV-01 advances to phase III with strong data, broadening access and maintaining solid financials - TradingView
RLMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Mov - Benzinga
RLMD Stock Chart | RELMADA THERAPEUTICS INC (NASDAQ:RLMD) - ChartMill
Relmada Therapeutics, Inc.Common Stock (NQ: RLMD - FinancialContent
RLMD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Relmada executives to present at Jefferies healthcare conference - Investing.com UK
Relmada TherapeuticsIncreases authorized common stock to 200 million shares from 150 million - marketscreener.com
Relmada (NASDAQ: RLMD) holders back higher share cap and equity plan - Stock Titan
Relmada executives to present at Jefferies healthcare conference By Investing.com - Investing.com Australia
Relmada Therapeutics (RLMD) to Present at the Jefferies Global Healthcare Conference - StreetInsider
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Relmada Therapeutics Increases Authorized Shares After Shareholder Vote - TipRanks
Relmada Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Relmada Therapeutics (RLMD) Edges Higher as Stock Holds Above Key SupportForce Index - newsline.com
Relmada Therapeutics Inc. (RLMD) Slips 2.36% as Stock Tests Key Support LevelsMA Crossover - The Legal Advocate
RLMD News | RELMADA THERAPEUTICS INC (NASDAQ:RLMD) - ChartMill
Earnings call transcript: Relmada Therapeutics Q1 2026 sees stock dip despite strong cash position By Investing.com - Investing.com South Africa
Earnings call transcript: Relmada Therapeutics Q1 2026 sees stock dip despite strong cash position - Investing.com
Relmada targets mid-2026 phase 3 RESCUE start backed by $234M cash runway through 2029 - MSN
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Relmada Therapeutics Charts Ambitious NDV-01 Phase 3 Path - TipRanks
Relmada Therapeutics Inc files for mixed shelf offering, size not disclosedSEC filing - marketscreener.com
Relmada Therapeutics Q1 earnings call highlights - MSN
Relmada Therapeutics (NASDAQ: RLMD) registers 29.5M shares tied to $160M deal - Stock Titan
Relmada Therapeutics Q1 Loss per Share Narrows - Moomoo
Adage Capital reports 4.54% stake in Relmada Therapeutics (NASDAQ: RLMD) - Stock Titan
Q1 2026 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Piper Sandler Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call Transcript - Insider Monkey
Relmada Therapeutics Reports Strong Q1 2026 Results, Highlights Positive NDV-01 Phase 2 Data in Bladder Cancer and Plans for Phase 3 RESCUE Program - Minichart
Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights - GuruFocus
Is Relmada Therapeutics (RLMD) Fairly Valued After Q1 2026? EPS: - GuruFocus
Relmada Therapeutics Q1 Earnings Call Highlights - sharewise.com
Transcript : Relmada Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026 - marketscreener.com
Relmada Highlights NDV-01 Phase 2 Data, Phase 3 Plans - TipRanks
Earnings call transcript: Relmada Therapeutics Q1 2026 results reveal mixed performance - Investing.com Nigeria
RLMD: NDV-01 shows best-in-class efficacy in NMIBC; cash and patent position support long-term growth - TradingView
RLMD: NDV-01 demonstrates high efficacy in NMIBC, with robust financials supporting late-stage trials - TradingView
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call - Benzinga
Relmada (NASDAQ: RLMD) boosts cash with $160M PIPE and NDV-01 data - Stock Titan
RLMD: NDV-01 demonstrates high response rates in NMIBC, with pivotal trials and strong financial backing ahead - TradingView
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Relmada Therapeutics Inc 주식 (RLMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
1.27%
1.43%
자본화:
|
볼륨(24시간):